Hope in that regard has been raised by the identification of ten novel glioblastoma-associated tumor antigens [18] whose curative potential as a multi-peptide vaccine, using CD8+ T cell epitopes, has been tested in phase I/II clinical trials [14]. This evidence concerns the gene CD8A and neoplasm.